therapeutic estradiol

BIOLOGICAL5 trials

Sponsors

Regional Oncologic Center, City of Hope Medical Center, University of Arizona, Mayo Clinic, University of Washington

Conditions

Advanced Triple-Negative Breast CarcinomaAnatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Breast CancerEstrogen Receptor-positive Breast CancerLocally Advanced Unresectable HER2-Negative Breast CarcinomaLocally Advanced Unresectable Hormone Receptor-Positive Breast CarcinomaMenopausal Symptoms

Phase 2

Deslorelin Combined With Low-Dose Add-Back Estradiol and Testosterone in Preventing Breast Cancer in Premenopausal Women Who Are at High Risk for This Disease

Active, not recruitingNCT00080756

City of Hope Medical Centerbrca1 Mutation Carrier, brca2 Mutation Carrier, Breast Cancer

Start: 2004-03-11End: 2024-10-15Updated: 2024-08-28

Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer

Active, not recruitingNCT03941730

Mayo ClinicAdvanced Triple-Negative Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 +2

Start: 2019-08-28End: 2026-12-31Updated: 2026-03-05

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

RecruitingNCT06179303

University of WashingtonAnatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Unresectable HER2-Negative Breast Carcinoma +3

Start: 2024-07-22End: 2028-06-01Target: 60Updated: 2026-02-27

Phase 3

Hormone Replacement Therapy and the Risk of Breast Cancer Recurrence in Women With Previous Early Stage Breast Cancer

CompletedNCT00003771

Regional Oncologic CenterBreast Cancer, Menopausal Symptoms

Start: 1997-09-30End: 2004-02-29Target: 1300Updated: 2013-09-20

Unknown Phase

Pilot Study Estradiol Followed by Exemestane Hormone Receptor + Metastatic Breast Cancer

CompletedNCT01385280

University of ArizonaEstrogen Receptor-positive Breast Cancer, Progesterone Receptor Positive Tumor, Recurrent Breast Cancer +2

Start: 2011-02-28End: 2013-10-31Updated: 2018-10-17

Related Papers

Abstract 1784: Functional characteristics of chemotherapy-resistance in triple negative breast cancer

Cancer Research2022-06-15

Abstract P4-02-09: The lncRNA XIST mediates sensitivity to ERβ targeted therapies in triple negative breast cancer

Cancer Research2022-02-151 citations